Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 03 2022 - 5:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
March 3, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Highlights
to be presented at Novo Nordisk’s Capital Markets Day 2022
Bagsværd, Denmark, 3 March 2022 – Novo Nordisk is today hosting
a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025.
The Strategic Aspirations 2025 were introduced in 2019 to reflect
the broad aspects of Novo Nordisk’s business including purpose and sustainability (ESG), the sustained growth opportunities until
2025 across therapy areas and geographies as well as future growth drivers of Novo Nordisk in the research and development pipeline.
The day will be centred around the Strategic Aspirations and during the day, senior
management presentations will cover corporate strategy and research and early development strategy, Environmental, Social and Governance
(ESG) strategies and performance as well as commercial strategies, research and development pipeline and performance within Diabetes care,
Obesity care and Biopharm, which is renamed to Rare Disease. In addition, Novo Nordisk’s approach to cardiovascular disease, product
supply and financials are presented.
The CMD will also include break-out sessions covering technology platforms, Non-alcoholic
steatohepatitis (NASH) and Alzheimer’s Disease (AD) and Region EMEA.
Key highlights of the day are:
| · | Focus on securing growth beyond semaglutide by building on core research capabilities and new technology
platforms |
| · | Growth potential for GLP-1-based semaglutide treatments within Diabetes care and outlook for the phase
3 clinical programme for insulin Icodec intended for once-weekly dosing |
| · | Launch update for Wegovy® in the US, where the expectation still is to be able to meet demand in the second half of 2022, an
updated commercial strategic aspiration for Obesity care and an update of the obesity research and development pipeline, including
the semaglutide 2.4 mg cardiovascular outcomes trial, SELECT |
| · | Update on the sustained growth aspiration for Rare Disease and clinical trial results from the phase 3 trial with Sogroya®
in children with growth hormone deficiency, results from the phase 1/2 trial with Mim8 in haemophilia A as well as results from the phase
3 clinical trial with concizumab in people with haemophilia A and B with inhibitors which was successfully completed in February 2022. |
All sessions of the CMD are webcasted live, and a replay will be made available
on the investor section of novonordisk.com. Presentation material from the CMD will also be available throughout the day on the investor
section of novonordisk.com.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and
headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare
blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent
and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Further information
Media: |
|
|
Martin Havtorn Petersen |
+45 3075 5246 |
mhpz@novonordisk.com |
Michael Bachner (US) |
+1 609 664 7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Jacob Martin Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
Mark Joseph Root (US) |
+1 848 213 3219 |
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 19 / 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: March 3, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024